ID	DDInter1975
	Drug Type	biotech
	Protein Chemical Formula	None
	Protein Average Weight	-
	CAS Number	-
	Description	Multiple myeloma is a cancer where plasma cells rapidly divide out of control.[A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.[A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab].[A232608] Idecabtagene vicleucel, also known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and [brexucabtagene autoleucel].[A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen.[A232558] The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain.[L32858] Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma.[L32858] Idecabtagene vicleucel was granted FDA approval on 26 March 2021.[L32863]
	ATC Classification	-
Sequences	None
Useful Links	DrugBank Wikipedia